MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation antibodies, today announced the addition of Jeffrey Ravetch, M.D., Ph.D., a leader in the study of Fc receptors for immunological research, to its Scientific Advisory Board. He is a professor and head of the Leonard Wagner Laboratory of Molecular Genetics and Immunology at The Rockefeller University, and joins Richard Lerner, M.D., Professor and President of the Scripps Research Institute, on Xencor’s advisory board.
